Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.

Autor: Kanagal-Shamanna R; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. RKanagal@mdanderson.org., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Katsonis P; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Class CA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sallman D; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Hunter AM; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Benton C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Luthra R; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Bueso-Ramos CE; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Komrokji RS; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Al Ali NH; Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, United States., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Routbort MJ; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Khoury JD; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Patel K; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ganan-Gomez I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wei Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Do KA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Soltysiak KA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lichtarge O; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States., Medeiros LJ; Department of Hematopathology and Molecular Diagnostics, Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2021 Mar 06; Vol. 11 (3), pp. 52. Date of Electronic Publication: 2021 Mar 06.
DOI: 10.1038/s41408-021-00446-y
Databáze: MEDLINE